TICKERNERD
Menu
ENTXENTXHealthcare · Biotechnology

ENTX Stock Forecast: Entera Bio Ltd. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$2.84
+1.79% on the day

The 1 Wall Street analysts covering Entera Bio Ltd. hold a median 12-month price target of $9 — +216.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 49 of 100 as at 12 Sept 2026 — in the lower half.

Market cap
$491.7M
Ticker Nerd rank
49 / 100
Median analyst target
$9.00
Analysts covering
1
Revenue$0.0
Operating income−$4.6M
Net income−$7.3M
Free cash flow−$3.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.7%
1M
−5.3%
YTD
+46.4%
1Y
+53.5%
From 52W high
−27.6%
From 52W low
+184.0%
$1.00
$3.92
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ENTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Entera Bio Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
49 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
76
Accruals
75
Volatility
70
Momentum
66
Size
53
Revisions
51
Growth
30
Quality
27
Issuance
24

Value (76): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (24): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ENTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ENTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Oct 25Jan 26Apr 26Jul 26ENTXHigh $9.00Median $9.00Low $9.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $9.00Median $9.00High $9.00

The green dot is the last close — the median target sits +216.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
27 Apr 2026HC Wainwright & Co.MaintainsBuy$10 → $9.00
27 Apr 2026HC Wainwright & Co.MaintainsBuy—
9 Feb 2026HC Wainwright & Co.ReiteratesBuy—
18 Mar 2025HC Wainwright & Co.ReiteratesBuy—
11 Nov 2024HC Wainwright & Co.ReiteratesBuy—
7 Oct 2024HC Wainwright & Co.ReiteratesBuy—
27 Sept 2024HC Wainwright & Co.ReiteratesBuy—
12 Aug 2024HC Wainwright & Co.ReiteratesBuy—
5 June 2024HC Wainwright & Co.ReiteratesBuy—
14 May 2024HC Wainwright & Co.ReiteratesBuy—
13 May 2024HC Wainwright & Co.ReiteratesBuy—
2 Apr 2024HC Wainwright & Co.MaintainsBuy—
11 Dec 2023HC Wainwright & Co.ReiteratesBuy—
13 Sept 2023HC Wainwright & Co.ReiteratesBuy—
11 Sept 2023HC Wainwright & Co.ReiteratesBuy—
8 May 2023HC Wainwright & Co.ReiteratesBuy—
4 Apr 2023HC Wainwright & Co.ReiteratesBuy—
28 Mar 2023HC Wainwright & Co.ReiteratesBuy—
6 Sept 2022HC Wainwright & Co.InitiatesBuy—
19 July 2022B. Riley SecuritiesMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ENTX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ENTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Entera Bio Ltd. returned +53.5% against +17.5% for the S&P 500, dividends included.

ENTX vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140160180Oct 25Jan 26Apr 26Jul 26ENTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ENTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Entera Bio Ltd. (ENTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−11.3×

Cheaper than 93% of US stocks

Price / sales
11707.7×

Cheaper than 1% of US stocks

Price / book
19.3×

Cheaper than 5% of US stocks

EV / EBITDA
−33.5×

Cheaper than 92% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−27450.0%

Higher than 1% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−138.9%

Higher than 10% of US stocks

Return on assets
−46.0%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Entera Bio Ltd. (ENTX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Entera Bio Ltd. has a market value of $491.7M and an enterprise value of $480.8M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$17.0M.

  • Free cash flow in the twelve months to 30 June 2026: −$11.0M.

  • Shares outstanding: 49.3M.

  • Trailing P/E: −11.3×; forward P/E: −5.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Entera Bio Ltd. employs 20 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

ENTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ENTXEntera Bio Ltd.$491.7M
49
IRDOpus Genetics, Inc.$491.6M
58
ZURAZura Bio Ltd.$494.3M
32
ARTVArtiva Biotherapeutics, Inc.$496.6M
38
VOGXVogenx, Inc.$485.9M
1
EIKNEikon Therapeutics, Inc.$483.7M
1
OVIDOvid Therapeutics, Inc.$502.1M
67

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Entera Bio Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ENTX news & analysis

Correction: Entera to Participate in Upcoming Fall Investor Conferences

GlobeNewsWire · 27 Aug 2026neutral

Entera Bio announced that its CEO, Miranda Toledano, will participate in upcoming fall investor conferences. The announcement was made on August 27, 2026, via GlobeNewsWire and corrects a prior release.

Why it matters — An ENTX watcher would care because the CEO's participation in investor conferences provides the company with opportunities to present its oral peptide development pipeline to the investment community.

Entera to Participate in Upcoming Fall Investor Conferences

GlobeNewsWire · 27 Aug 2026neutral

Entera Bio announced that CEO Miranda Toledano will participate in upcoming fall investor conferences, including a fireside chat at the 2026 Cantor Global Healthcare Conference on September 10, 2026 at 1:00 p.m.

Why it matters — The CEO's participation in investor conferences provides ENTX watchers with opportunities to hear directly from management about the company's oral peptide development program.

Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation

GlobeNewsWire · 18 Aug 2026positive

Entera Bio Ltd. announced the appointment of Riccardo Paolo Camisasca, M.D., as Chief Medical Officer ahead of its planned EB613 Phase 3 initiation. Camisasca brings 30 years of global pharmaceutical research and clinical development experience from roles at Sumitomo Pharma, Takeda, and Novartis.

Why it matters — A watcher would care because the appointment strengthens Entera's clinical execution and late-stage development capabilities as the company prepares to initiate its planned EB613 Phase 3 trial.

Entera Bio Eyes Phase 3 Start for Oral Osteoporosis Drug EB613 After FDA Agreement

MarketBeat · 13 Aug 2026positive

Entera Bio has reached an agreement with the FDA on a 12-month, placebo-controlled registrational trial design for its oral osteoporosis drug candidate EB613, and plans to begin a Phase 3 study.

Why it matters — The FDA agreement clears a key regulatory path for EB613, moving Entera Bio's lead candidate closer to potential approval in the osteoporosis space.

Entera Announces Second Quarter 2026 Financial Results and Business Updates

GlobeNewsWire · 7 Aug 2026positive

Entera Bio Ltd. announced its second quarter 2026 financial results and reported that the FDA has aligned on a 12-month registrational Phase 3 study design to support a New Drug Application for EB613, the first oral anabolic tablet in development for postmenopausal women with osteoporosis.

Why it matters — FDA agreement on a Phase 3 registrational study for EB613 brings Entera's lead candidate one step closer to a potential NDA submission, marking a significant clinical and regulatory milestone for the company.

FAQ

Frequently asked questions about ENTX stock

What is the ENTX stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Entera Bio Ltd. have a median 12-month price target of $9, with estimates ranging from $9 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ENTX stock a buy right now?

Of the 1 analysts covering Entera Bio Ltd., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Entera Bio Ltd. 49 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ENTX?

As at 12 Sept 2026, Entera Bio Ltd. ranks 49 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (76 of 100).

Will ENTX stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +216.9% from the last close, and Ticker Nerd's factor model ranks Entera Bio Ltd. 49 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ENTX stock forecast for 2030?

No analyst covering Entera Bio Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ENTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $9 over the next 12 months.

How has ENTX stock performed over the past year?

Entera Bio Ltd. returned +53.5% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Entera Bio Ltd. do?

Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on developing orally delivered peptide and protein replacement therapies for serious unmet medical needs.

What is the latest news on ENTX?

The most recent item we track (GlobeNewsWire, 27 Aug 2026): "Correction: Entera to Participate in Upcoming Fall Investor Conferences". Entera Bio announced that its CEO, Miranda Toledano, will participate in upcoming fall investor conferences. The announcement was made on August 27, 2026, via GlobeNewsWire and corrects a prior release.

Company

About Entera Bio Ltd.

Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on developing orally delivered peptide and protein replacement therapies for serious unmet medical needs. Its work centers on converting complex therapies that are typically injected into mini-tablet formats designed for easier administration and improved patient adherence. The company’s technology platform supports oral delivery by stabilizing peptides in the gastrointestinal tract and enhancing absorption into the bloodstream. Entera Bio’s current pipeline includes programs targeting bone, endocrine, and metabolic disorders, with research spanning parathyroid hormone, GLP-1, and GLP-2-based therapies. The company also pursues collaborations and licensing opportunities to advance its oral drug delivery platform across selected therapeutic areas. Headquartered in Jerusalem, Israel, Entera Bio plays a specialized role in the biopharmaceutical market by addressing delivery challenges that limit the use of large-molecule medicines.

CEO Ms. Miranda J. Toledano M.B.A. · 20 employees · Israel · https://enterabio.com